NEW YORK (GenomeWeb News) – Arrayjet and Fios Genomics announced on Wednesday a deal to offer "a complete, end-to-end microarray solution" to their customers.
Claire Jenkins, Arrayjet's commercial director told GenomeWeb Daily News in an e-mail that the firms will co-promote their combined service offering.
"Rather than both companies targeting the same companies with niche offerings we are working together to maximize the effect," she said. "Both Arrayjet and Fios will still have individual commercial teams and strategies but see the benefit of also offering a linked-up approach."
Financial terms were not disclosed.
"We believe by developing our strategy to become a complete solutions provider, we are better placed to help our customers achieve good quality data on which to make decisions, by either providing an instrument, printed slides, or full microarray services with data analysis" Iain McWilliam, CEO of Roslin, Scotland-based Arrayjet, said in a statement.
Fios Genomics CEO Bill Buckie added, "In particular, customers who are interested in profiling protein and peptide expression changes, such as in a clinical environment and for biomarker classification, can come to either Fios Genomics or Arrayjet for a joined-up service offering including the supply of custom microarrays, sample preparation, proteomic data generation and analysis of the data.”
Fios Genomics, headquartered in Edinburgh, Scotland, provides genomic and bioinformatics data analysis services to pharma firms, contract research organizations, and academia for drug discovery and development and applied research.